Edwards Lifesciences Corporation Research and Development Asset Acquired Other than Through Business Combination, Written-off
Edwards Lifesciences Corporation (EW) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2022-02-14
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for the quarter ending 2020-12-31 was $0.00.
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for the quarter ending 2020-09-30 was $0.00.
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for the quarter ending 2020-06-30 was $0.00.
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for fiscal 2021 was $0.00.
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for fiscal 2019 was $24.00M.
- Edwards Lifesciences Corporation research and development asset acquired other than through business combination, written-off for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 1 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-14 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | $0.00 derived: sum of 3 quarters · filed 2022-02-14 | $0.00 10-K · filed 2022-02-14 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $0.00 derived: sum of 2 quarters · filed 2020-10-26 | $0.00 10-Q · filed 2020-10-26 | $0.00 derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $0.00 10-Q · filed 2020-07-27 | $0.00 derived: sum of 3 quarters · filed 2022-02-14 | $0.00 derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-04-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | $0.00 derived: sum of 3 quarters · filed 2022-02-14 | $0.00 derived: sum of 4 quarters · filed 2022-02-14 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | $0.00 derived: sum of 3 quarters · filed 2022-02-14 | $24.00M 10-K · filed 2022-02-14 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $0.00 derived: sum of 2 quarters · filed 2020-10-26 | $24.00M 10-Q · filed 2020-10-26 | $24.00M derived: sum of 4 quarters · filed 2021-02-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $24.00M 10-Q · filed 2020-07-27 | $24.00M derived: sum of 3 quarters · filed 2021-02-12 | $24.00M derived: sum of 4 quarters · filed 2021-02-12 | |
| 2019-03-31 | $24.00M 10-Q · filed 2020-10-26 | $24.00M 10-Q · filed 2020-04-28 | $24.00M derived: sum of 2 quarters · filed 2021-02-12 | $24.00M derived: sum of 3 quarters · filed 2021-02-12 | $24.00M derived: sum of 4 quarters · filed 2021-02-12 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $0.00 derived: sum of 2 quarters · filed 2021-02-12 | $0.00 derived: sum of 3 quarters · filed 2021-02-12 | $0.00 10-K · filed 2021-02-12 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-25 | $0.00 derived: sum of 2 quarters · filed 2019-10-25 | $0.00 10-Q · filed 2019-10-25 | $0.00 derived: sum of 4 quarters · filed 2020-02-14 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-26 | $0.00 10-Q · filed 2019-07-26 | $0.00 derived: sum of 3 quarters · filed 2020-02-14 | $1.00M derived: sum of 4 quarters · filed 2020-02-14 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-04-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-14 | $1.00M derived: sum of 3 quarters · filed 2020-02-14 | $1.10M derived: sum of 4 quarters · filed 2020-02-14 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $1.00M derived: sum of 2 quarters · filed 2020-02-14 | $1.10M derived: sum of 3 quarters · filed 2020-02-14 | $6.70M 10-K · filed 2020-02-14 | |
| 2017-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $1.10M derived: sum of 2 quarters · filed 2018-07-27 | $6.70M 10-Q · filed 2017-10-27 | $6.70M derived: sum of 4 quarters · filed 2019-02-15 | |
| 2017-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-27 | $5.70M 10-Q · filed 2018-07-27 | $5.70M derived: sum of 3 quarters · filed 2019-02-15 | $5.70M derived: sum of 4 quarters · filed 2019-02-15 | |
| 2017-03-31 | $5.60M 10-Q · filed 2018-04-27 | $5.60M derived: sum of 2 quarters · filed 2019-02-15 | $5.60M derived: sum of 3 quarters · filed 2019-02-15 | $40.10M derived: sum of 4 quarters · filed 2019-02-15 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $0.00 derived: sum of 2 quarters · filed 2019-02-15 | $34.50M derived: sum of 3 quarters · filed 2019-02-15 | $34.50M 10-K · filed 2019-02-15 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $34.50M derived: sum of 2 quarters · filed 2017-10-27 | $34.50M 10-Q · filed 2017-10-27 | ||
| 2016-06-30 | $34.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $34.50M 10-Q · filed 2017-07-28 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-04-28 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-16 | ||||
| 2014-12-31 | $10.60M 10-K · filed 2017-02-17 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-19 | ||||
| 2012-12-31 | $7.00M 10-K · filed 2015-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |